

# The Role of Economic Analysis at NIST

Gary Anderson  
Economist  
Office of the Director

**NIST**

**National Institute of  
Standards and Technology**

Technology Administration  
U.S. Department of Commerce



# NIST's Role in Innovation

## NIST Mission


To promote U.S. innovation and industrial competitiveness by advancing

**measurement science**, **standards**,  
and **technology**

in ways that enhance economic security and improve the quality of life for all Americans.

# NIST's Role in Innovation

*Infratechnology impacts every stage of innovation*



# Economics & Strategic Planning

## *The Cost of Not Having Critical Infratechnologies*

<b>Focus of Study</b>	<b>Infrastructure Studied</b>	<b>Industries Covered</b>	<b>Estimated Annual Costs of Inadequate Infrastructure</b>
Interoperability costs (1999)	<ul style="list-style-type: none"> <li>• Product design data exchange</li> </ul>	<ul style="list-style-type: none"> <li>• Automotive supply chain</li> </ul>	\$1 billion
Deregulation (2000)	<ul style="list-style-type: none"> <li>• Metering</li> <li>• Systems monitoring/control</li> </ul>	<ul style="list-style-type: none"> <li>• Electric utilities</li> </ul>	\$3.1–\$6.5 billion
Software testing (2002)	<ul style="list-style-type: none"> <li>• All stages of the testing cycle</li> </ul>	<ul style="list-style-type: none"> <li>• Transportation equipment</li> <li>• Financial services</li> <li>• Extrapolation to entire U.S.</li> </ul>	\$1.8 billion \$3.3 billion \$60 billion
Interoperability costs (2004)	<ul style="list-style-type: none"> <li>• Business data exchange: production scheduling, inventory management, procurement, and distribution/marketing</li> </ul>	<ul style="list-style-type: none"> <li>• Automotive supply chain</li> <li>• Electronics supply chain</li> </ul>	\$5 billion \$3.9 billion
Interoperability costs (2004)	<ul style="list-style-type: none"> <li>• Business data exchange: design &amp; engineering, construction, and operations &amp; maintenance</li> </ul>	<ul style="list-style-type: none"> <li>• Construction/building systems management</li> </ul>	\$15.8 billion
Medical testing (2004)	<ul style="list-style-type: none"> <li>• Quality of measurement assurance</li> </ul>	<ul style="list-style-type: none"> <li>• Laboratories (calcium)</li> </ul>	\$0.06–\$0.199 billion

# Demonstrating NIST Impact

## *Economic Studies Performed*

- Average benefit-cost ratio of 44:1 in 19 studies since 1996
- Estimates of direct impacts only; no multiplier effect estimated
- Caveat – selection of projects based on perceived existence of industry impact; not randomly selected
- Topics cover wide range of technologies and industries and can be collectively viewed as a legitimate indicator of NIST industry impact

# Demonstrating NIST Impact

## Sample of Retrospective Economic Impact Studies: Outputs and Outcomes of NIST Laboratory Research

Industry/Project	Output	Outcomes	Measure
<b>Chemicals:</b> Standards for sulfur in fossil fuels (2000)	<ul style="list-style-type: none"> <li>• Measurement methods</li> <li>• Reference materials</li> </ul>	<ul style="list-style-type: none"> <li>• Increase R&amp;D Efficiency</li> <li>• Increase productivity</li> <li>• Reduce transaction costs</li> </ul>	IRR: 1,056% BCR: 113 NPV: \$409M
<b>Semiconductors:</b> Josephson volt standard (2001)	<ul style="list-style-type: none"> <li>• Measurement methods</li> <li>• Reference materials</li> </ul>	<ul style="list-style-type: none"> <li>• Increase R&amp;D efficiency</li> <li>• Enable new markets</li> </ul>	IRR: 877% BCR: 5 NPV: \$42M
<b>Communications:</b> Data encryption standard (2001)	<ul style="list-style-type: none"> <li>• Standard (DES)</li> <li>• Conformance test methods</li> </ul>	<ul style="list-style-type: none"> <li>• Accelerate new markets</li> <li>• Increase R&amp;D efficiency</li> </ul>	IRR: 270% BCR: 58–145 NPV: \$345M–\$1.2B
<b>Communications:</b> Role-based access control (2001)	<ul style="list-style-type: none"> <li>• Generic technology</li> <li>• Reference models</li> </ul>	<ul style="list-style-type: none"> <li>• Enable new markets</li> <li>• Increase R&amp;D efficiency</li> </ul>	IRR: 29–44% BCR: 43–99 NPV: \$59–138M
<b>Energy:</b> Gas mixture standard for regulatory compliance (2002)	<ul style="list-style-type: none"> <li>• Standard (NTRM)</li> </ul>	<ul style="list-style-type: none"> <li>• Increase productivity</li> <li>• Reduce transaction costs</li> </ul>	IRR: 221–228% BCR: 21–27 NPV: \$49–63M
<b>Manufacturing:</b> Product design data standard (2002)	<ul style="list-style-type: none"> <li>• Standard (STEP)</li> <li>• Conformance test methods/facilities</li> </ul>	<ul style="list-style-type: none"> <li>• Increase R&amp;D efficiency</li> <li>• Reduce transaction costs</li> </ul>	IRR: 32% BCR: 8 NPV: \$180M

IRR=Internal (Social) Rate of Return, BCR=Benefit-Cost Ratio and NPV=Net Present Value.

Studies available at [http://www.nist.gov/public\\_affairs/budget.htm](http://www.nist.gov/public_affairs/budget.htm)

# Recent and Ongoing Analysis

## Programmatic Studies

- **Economic Impact of Measurement in the Semiconductor Industry**
  - Calculated the investments and benefits of measurement science investments as well as other measurement-related activities
  - 1996–2006 semiconductor supply chain invested \$12.3 billion measurement expenditure (in 2006 dollars).
  - Estimates of economic benefits accruing between 1997 and 2011, which stemmed from investments made between 1996 and 2006 are Net present value: \$17 billion Benefit-cost ratio: 3.3 Internal rate of return: 67%

## More microeconomic project studies

- **Prospective Planning studies: Technology Infrastructure Needs of the U.S. Biopharmaceutical Industry**
  - Industry currently spends: \$21 billion per year on R&D; 1.2 billion per year on technology infrastructure
  - Probability of FDA approval for a drug candidate could be increased from 30 to 40 percent
  - Expenditures for a new FDA-approved drug could be reduced from between 25 and 48 percent (to between \$289 million and \$421 million, compared to a current baseline cost estimate of \$560 million)
  - Time to move from discovery through clinical trials could be reduced from 11 years to as little as 8 year
- **Retrospective Impact studies**
  - Several On-Going

## Other retrospective analysis

- **Econometric studies based on linked firm and establishment level data**
- **Bibliometric analysis**

# Moving Forward

## *Increased Importance of Effective Budget Allocation*

### **NIST Laboratory Budget Relative to Industry-Funded R&D**

